Benitec Biopharma Inc’s recently made public that its Director SUVRETTA CAPITAL MANAGEMENT, L acquired Company’s shares for reported $0.21 million on Mar 31 ’25. In the deal valued at $12.83 per share,16,497 shares were bought. As a result of this transaction, SUVRETTA CAPITAL MANAGEMENT, L now holds 8,807,805 shares worth roughly $135.99 million.
Then, SUVRETTA CAPITAL MANAGEMENT, L bought 900,000 shares, generating $11,700,000 in total proceeds. Upon buying the shares at $13.00, the Director now owns 8,793,245 shares.
Before that, SUVRETTA CAPITAL MANAGEMENT, L bought 27,502 shares. Benitec Biopharma Inc shares valued at $301,972 were divested by the Director at a price of $10.98 per share. As a result of the transaction, SUVRETTA CAPITAL MANAGEMENT, L now holds 7,981,725 shares, worth roughly $123.24 million.
H.C. Wainwright initiated its Benitec Biopharma Inc [BNTC] rating to a Buy in a research note published on December 16, 2024; the price target was $28. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Oppenheimer began covering BNTC with “an Outperform” recommendation on October 16, 2024. Guggenheim started covering the stock on September 12, 2024. It rated BNTC as “a Buy”.
Price Performance Review of BNTC
On Tuesday, Benitec Biopharma Inc [NASDAQ:BNTC] saw its stock fall -1.97% to $15.44. Over the last five days, the stock has lost -4.57%. Benitec Biopharma Inc shares have risen nearly 22.25% since the year began. Nevertheless, the stocks have risen 106.42% over the past one year. While a 52-week high of $17.15 was reached on 06/10/25, a 52-week low of $5.74 was recorded on 02/13/25.
Levels Of Support And Resistance For BNTC Stock
The 24-hour chart illustrates a support level at 14.89, which if violated will result in even more drops to 14.33. On the upside, there is a resistance level at 16.04. A further resistance level may holdings at 16.63.
The most recent change occurred on July 22, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $13 price target.
